869882-72-4

Usage

Uses

Used in Organic Synthesis:
(S)-tert-Butyl 3-(4-aminophenyl)-2-(((benzyloxy)carbonyl)amino)propanoate is used as a building block in the synthesis of various organic compounds. Its unique structure allows it to be a valuable component in the creation of pharmaceutical drugs and biologically active molecules, contributing to the development of new and innovative chemical entities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (S)-tert-Butyl 3-(4-aminophenyl)-2-(((benzyloxy)carbonyl)amino)propanoate is used as a key intermediate in the production of pharmaceutical drugs. Its chemical properties and reactivity make it suitable for the synthesis of a wide range of therapeutic agents, potentially leading to the discovery of new medications with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
(S)-tert-Butyl 3-(4-aminophenyl)-2-(((benzyloxy)carbonyl)amino)propanoate is utilized in medicinal chemistry for the exploration of its pharmacological properties and biological activities. Its chemical structure may confer specific interactions with biological targets, making it a promising candidate for further research and development in the discovery of novel therapeutic agents.

Upstream product

• 869882-71-3 C₂₁H₂₄N₂O₆ 
• 190579-73-8 2-benzyloxycarbonylamino-3-iodo-propionic acid tert-butyl ester 
• 540-37-4 p-aminoiodobenzene 

Downstream Products

• 873686-75-0 C₂₆H₂₈N₄O₆ 
• 869882-73-5 C₂₂H₂₄N₂O₅ 

Relevant academic research and scientific papers

PREPARATION OF POLYMER CONJUGATES OF THERAPEUTIC, AGRICULTURAL, AND FOOD ADDITIVE COMPOUNDS

Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.

Multimeric VLA-4 antagonists comprising polymer moieties

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS

Disclosed are compounds of the f ormula : and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Synthesis of chiral amino acids with metal ion chelating side chains from L-serine using Negishi cross-coupling reaction

The scope of the Negishi cross-coupling reaction of organozinc compounds derived from chiral amino acids was extended to electron rich iodoanilines and iodobenzylamines as coupling reagents. The protocol allows the direct modification of serine into pheny

Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.